{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:47Z","timestamp":1792178987511,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11926-019-0862-5","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:04:02Z","timestamp":1574139842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-1821","authenticated-orcid":false,"given":"Dana","family":"DiRenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-8392","authenticated-orcid":false,"given":"Christopher A.","family":"Mecoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"862_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","volume":"32","author":"MM Dimachkie","year":"2014","unstructured":"Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Neurol Clin. 2014;32:595\u2013628.","journal-title":"Neurol Clin"},{"key":"862_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"\u2022 Rider LG, Aggarwal R, Machado PM, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14:303\u201318 This study provides a comprehensive overview of outcome measures, including PROMs, used in both juvenile and adult IIM.","journal-title":"Nat Rev Rheumatol"},{"key":"862_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMp1707537","volume":"377","author":"LS Rotenstein","year":"2017","unstructured":"Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier \u2014 the potential of patient-reported outcomes. N Engl J Med. 2017;377:1309\u201312.","journal-title":"N Engl J Med"},{"key":"862_CR4","unstructured":"Locklear T, Weinfurt KAA. Resource chapters: patient-reported outcomes. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials."},{"key":"862_CR5","unstructured":"General info Sub Page, https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/QualityInitiativesGenInfo\/MMF\/General-info-Sub-Page.html (2018, accessed 14 April 2019)."},{"key":"862_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","volume":"43","author":"DA Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology. 2004;43:49\u201354.","journal-title":"Rheumatology"},{"key":"862_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160753","volume":"11","author":"V Leclair","year":"2016","unstructured":"Leclair V, Regardt M, Wojcik S, Hudson M, Canadian Inflammatory Myopathy Study (CIMS). Health-related quality of life (HRQoL) in idiopathic inflammatory myopathy: a systematic review. PLoS One. 2016;11:e0160753.","journal-title":"PLoS One"},{"key":"862_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1745-6215-8-38","volume":"8","author":"P Tugwell","year":"2007","unstructured":"Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials. 2007;8:38.","journal-title":"Trials"},{"key":"862_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3899\/jrheum.131247","volume":"41","author":"H Alexanderson","year":"2014","unstructured":"Alexanderson H, Del Grande M, Bingham CO, et al. Patient-reported outcomes and adult patients\u2019 disease experience in the idiopathic inflammatory myopathies. Report from the OMERACT 11 myositis special interest group. J Rheumatol. 2014;41:581\u201392.","journal-title":"J Rheumatol"},{"key":"862_CR10","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.3899\/jrheum.141243","volume":"42","author":"M Regardt","year":"2015","unstructured":"Regardt M, Basharat P, Christopher-Stine L, Sarver C, Bj\u00f6rn A, Lundberg IE, et al. Patients\u2019 experience of myositis and further validation of a myositis-specific patient reported outcome measure \u2014 establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12. J Rheumatol. 2015;42:2492\u20135.","journal-title":"J Rheumatol"},{"issue":"10","key":"862_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3899\/jrheum.181065","volume":"46","author":"Malin Regardt","year":"2019","unstructured":"\u2022 Regardt M, Mecoli CA, Park JK, et al. OMERACT 2018 modified patient-reported outcome domain Core set in the life impact area for adult idiopathic inflammatory myopathies. J Rheumatol. 2019. https:\/\/doi.org\/10.3899\/jrheum.181065 Summarizes the process of the OMERACT Myositis Special Interest Group and the steps taken to derive a core set of domains that are relevant to adult patients with IIM.","journal-title":"The Journal of Rheumatology"},{"key":"862_CR12","unstructured":"International Myositis Assessment & Clinical Studies Group (IMACS), https:\/\/www.niehs.nih.gov\/research\/resources\/imacs\/index.cfm (accessed 10 April 2019)."},{"key":"862_CR13","unstructured":"Aggarwal R, Rider LG, Ruperto N, et al. League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ARTHRITIS Rheumatol 2017; 00: 0\u201300."},{"key":"862_CR14","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1002\/acr.20541","volume":"63","author":"L Busija","year":"2011","unstructured":"Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Sh. Arthritis Care Res (Hoboken). 2011;63:S383\u2013412.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"862_CR15","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ). Arthritis Care Res (Hoboken). 2011;63:S118\u201357.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"862_CR16","first-page":"603","volume":"30","author":"LG Rider","year":"2003","unstructured":"Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30:603\u201317.","journal-title":"J Rheumatol"},{"key":"862_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.","journal-title":"Health Qual Life Outcomes"},{"key":"862_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14:303\u201318.","journal-title":"Nat Rev Rheumatol"},{"key":"862_CR19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","volume":"40","author":"FW Miller","year":"2001","unstructured":"Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40:1262\u201373.","journal-title":"Rheumatology (Oxford)"},{"key":"862_CR20","unstructured":"36-Item Short Form Survey (SF-36) Scoring Instructions | RAND, https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form\/scoring.html (accessed 12 April 2019)."},{"key":"862_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.4730020305","volume":"2","author":"RD Hays","year":"1993","unstructured":"Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993;2:217\u201327.","journal-title":"Health Econ"},{"key":"862_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3109\/07853890109002089","volume":"33","author":"RD Hays","year":"2001","unstructured":"Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350\u20137.","journal-title":"Ann Med"},{"key":"862_CR23","unstructured":"PROMIS: Clinical Outcomes Assessment, https:\/\/commonfund.nih.gov\/promis\/index (accessed 9 December 2018)."},{"key":"862_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63:1179\u201394.","journal-title":"J Clin Epidemiol"},{"key":"862_CR25","unstructured":"PROMIS: Clinical Outcomes Assessment \u2014 Research Tools, https:\/\/commonfund.nih.gov\/promis\/tools (accessed 22 April 2019)."},{"key":"862_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/acr.23617","volume":"71","author":"A Wohlfahrt","year":"2019","unstructured":"Wohlfahrt A, Bingham CO, Marder W, et al. Responsiveness of Patient-Reported Outcomes Measurement Information System measures in rheumatoid arthritis patients starting or switching a disease-modifying antirheumatic drug. Arthritis Care Res (Hoboken). 2019;71:521\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"862_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138543","volume":"10","author":"SJ Bartlett","year":"2015","unstructured":"Bartlett SJ, Orbai A-M, Duncan T, DeLeon E, Ruffing V, Clegg-Smith K, et al. Reliability and validity of selected PROMIS measures in people with rheumatoid arthritis. PLoS One. 2015;10:e0138543.","journal-title":"PLoS One"},{"key":"862_CR28","doi-asserted-by":"crossref","unstructured":"Werth VP, Patel B, Concha JS, et al. SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001. In: Saturday, 16 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism. p. 1111.3\u20131112.","DOI":"10.1136\/annrheumdis-2018-eular.5629"},{"key":"862_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11136-017-1709-z","volume":"27","author":"V Nagaraja","year":"2018","unstructured":"Nagaraja V, Mara C, Khanna PP, Namas R, Young A, Fox DA, et al. Establishing clinical severity for PROMIS\u00ae measures in adult patients with rheumatic diseases. Qual Life Res. 2018;27:755\u201364.","journal-title":"Qual Life Res"},{"key":"862_CR30","first-page":"447","volume":"19","author":"YL Chung","year":"2001","unstructured":"Chung YL, Mitchell HL, Houssien DA, et al. A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile. Clin Exp Rheumatol. 2001;19:447\u201350.","journal-title":"Clin Exp Rheumatol"},{"key":"862_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00019053-200017010-00002","volume":"17","author":"SJ Coons","year":"2000","unstructured":"Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13\u201335.","journal-title":"Pharmacoeconomics"},{"key":"862_CR32","first-page":"2386","volume":"29","author":"H Alexanderson","year":"2002","unstructured":"Alexanderson H, Lundberg IE, Stenstr\u00f6m CH. Development of the myositis activities profile\u2014validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis\/dermatomyositis. J Rheumatol. 2002;29:2386\u201392.","journal-title":"J Rheumatol"},{"key":"862_CR33","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3899\/jrheum.120504","volume":"39","author":"H Alexanderson","year":"2012","unstructured":"Alexanderson H, Reed AM, Ytterberg SR. The myositis activities profile \u2014 initial validation for assessment of polymyositis\/dermatomyositis in the USA. J Rheumatol. 2012;39:2134\u201341.","journal-title":"J Rheumatol"},{"key":"862_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.1780350102","volume":"35","author":"RF Meenan","year":"1992","unstructured":"Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales health status questionnaire. Arthritis Rheum. 1992;35:1\u201310.","journal-title":"Arthritis Rheum"},{"key":"862_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314\u201324.","journal-title":"Arthritis Rheum"},{"key":"862_CR36","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281\u201390.","journal-title":"Arthritis Rheum"},{"key":"862_CR37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66:740\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"862_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77:720\u20137.","journal-title":"Ann Rheum Dis"},{"key":"862_CR39","unstructured":"Wagle NW. Implementing Patient-Reported Outcome Measures (PROMs), https:\/\/catalyst.nejm.org\/implementing-proms-patient-reported-outcome-measures\/ ()."},{"key":"862_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jclinepi.2017.04.014","volume":"89","author":"CO Bingham","year":"2017","unstructured":"Bingham CO, Noonan VK, Auger C, et al. Montreal Accord on patient-reported outcomes (PROs) use series \u2013 paper 4: patient-reported outcomes can inform clinical decision making in chronic care. J Clin Epidemiol. 2017;89:136\u201341.","journal-title":"J Clin Epidemiol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0862-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-019-0862-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0862-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T04:49:01Z","timestamp":1605674941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-019-0862-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s11926-019-0862-5","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"19 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Bingham reports serving as an Executive Committee member for Outcome Measures in Rheumatology (OMERACT), which received hands-off funding from more than 20 pharmaceutical and research organizations. He receives no financial remuneration for this role. Dr. DiRenzo has nothing to disclose. Dr. Mecoli has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"62"}}